Study to Determine Effect of Exendin-9,39 Infusion on Insulin Secretion

Overview

About this study

The purpose of this study is to determine the effect of duration of exendin-9,39 infusion on insulin secretion.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Previous study participants.
Eligible subjects willing too come to the CRTU for a screening visit.

Exclusion Criteria:

Age <20 or >65.
BMI <18 or >35 Kg/M2.
For female subjects a positive pregnancy test.
Any systemic illness.
History of chronic medical illnesses.
Any medication that could affect glucose metabolism
Prior abdominal surgery other than cholecystectomy, appendectomy or tubal ligation.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Adrian Vella, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials